Abstract
Targeted treatments such as sunitinib and everolimus are providing exciting new options for the management of pancreatic neuroendocrine tumours (pNETs). Clinical management of patients receiving targeted therapies aims to maximise the benefits patients achieve whilst minimising the impact of side effects to maintain quality of life. Adverse event management requires physicians to control co-morbidities, carefully review medication histories and to educate and support patients prior to receiving new treatments. Individual strategies to control specific common side effects such as fatigue, diarrhoea and stomatitis should be employed to allow optimal treatment duration and maintenance of dose intensity; all of which are key to ensure maximum benefit is derived from any treatment option. Recognising and acknowledging the difficulties patients may experience with adherence to chronic medications, and providing strategies to overcome them is a further important component of patient care. At the core of clinical management is effective communication between patients and physicians, which ensures patients are fully involved in decisions concerning their care, and will allow advances in the use of targeted therapies to be translated into benefits for individual patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yao JC et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072
Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513
Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523
Pavel ME et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012
Hubner RA, Valle JW (2011) Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 11(12):1817–1827
Gore ME et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763
Porta C et al (2008) Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. In: ASCO meeting abstract
Schwandt A et al (2009) Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2:51–61
Negrier S, Ravaud A (2007) Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer 5(7):12–19
Rock EP et al (2007) Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12(1):107–113
Brock MV et al (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358(11):1118–1128
Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl 2):32–44
Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6:41–51
Bhojani N et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53(5):917–930
Ravaud A (2009) How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 20(Suppl 1):i7–i12
Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 12(9):626–633
Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73(2):156–166
Schmidinger M et al (2010) Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 28(8):856–864
Eisen T et al (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93–113
O’Brien BE, Kaklamani VG, Benson AB 3rd (2005) The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer 4(6):375–381 (discussion 382–383)
Degen A et al (2010) The hand-foot-syndrome associated with medical tumor therapy: classification and management. J Dtsch Dermatol Ges 8(9):652–661
Porta C, Szczylik C (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 35(3):297–307
Rini BI et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1):81–83
Beaumont JL et al (2012) Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3):461–466
Raymond E et al (2010) Evidence of activity and clinical benefit with sunitinib in patients with pancreatic neuroendocrine tumours. In: 12th World congress on gastrointestinal cancer. Barcelona, Spain
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15
Houk BE et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357–371
Negrier S (2012) Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices. Oncology 82(4):189–196
Le Tourneau C et al (2012) Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer 106(5):854–857
Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661
Andrade SE et al (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574 (discussion 575–577)
Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606
Levine AM et al (1987) Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 5(9):1469–1476
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497
Wang PS et al (2002) Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 17(7):504–511
Love RR et al (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151(9):1842–1847
Pollak KI et al (2007) Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 25(36):5748–5752
Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288(22):2880–2883
Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60(9):869–875
Arnold-Worner N et al (2008) The importance of specialist treatment, treatment satisfaction and diabetes education for the compliance of subjects with type 2 diabetes: results from a population-based survey. Exp Clin Endocrinol Diab 116(2):123–128
Haynes RB et al (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002(2):CD000011
Roter DL et al (1998) Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 36(8):1138–1161
Bitar R et al (2004) Does tumor status influence cancer patients’ satisfaction with the doctor-patient interaction? Support Care Cancer 12(1):34–40
Greenfield S, Kaplan S, Ware JE Jr (1985) Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 102(4):520–528
Baile WF, Aaron J (2005) Patient-physician communication in oncology: past, present, and future. Curr Opin Oncol 17(4):331–335
Bredart A, Bouleuc C, Dolbeault S (2005) Doctor-patient communication and satisfaction with care in oncology. Curr Opin Oncol 17(4):351–354
Fallowfield L et al (2003) Enduring impact of communication skills training: results of a 12-month follow-up. Br J Cancer 89(8):1445–1449
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag France
About this chapter
Cite this chapter
Carter, L., Hubner, R.A., Valle, J.W. (2014). Clinical Management of Targeted Therapies in Neuroendocrine Tumours. In: Raymond, E., Faivre, S., Ruszniewski, P. (eds) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract. Springer, Paris. https://doi.org/10.1007/978-2-8178-0430-9_10
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0430-9_10
Published:
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0429-3
Online ISBN: 978-2-8178-0430-9
eBook Packages: MedicineMedicine (R0)